StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Aggregate of 8 sell-side ratings as of 2026-05-01. Stonvex does not endorse these ratings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Next report date, year-over-year trend, and recent quarter history.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $10.69 | $10.63 | -0.56% | 0.1M |
| 05-18 | $10.65 | $9.57 | -10.14% | 0.2M |
| 05-19 | $9.57 | $9.17 | -4.18% | 0.1M |
| 05-20 | $9.35 | $9.97 | +6.63% | 0.1M |
| 05-21 | $10.06 | $9.90 | -1.59% | 0.1M |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows ELTX's percentile within the scored universe — observational ranking, not a recommendation.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-05 | Q1 2023 2023-03-31 | Annual 2022 2022-12-31 | Q3 2022 2022-09-30 | Q2 2022 2022-06-30 |
|---|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $2.30M | $2.30M | $2.30M |
Operating Income | Not available | $-7.80M | $-23.73M | $-17.77M | $-12.00M |
Net Income | Not available | $-8.03M | $-28.21M | $-21.56M | $-7.30M |
EPS (Diluted) | $-0.48 | $-24.77 | $-89.27 | $-68.52 | $-45.85 |
Total Assets | Not available | $41.77M | $22.66M | $61.32M | $70.81M |
Total Liabilities | Not available | $2.10M | $13.75M | $11.11M | $11.05M |
Cash & Equivalents | Not available | $8.57M | $6.16M | $1.84M | $598.00K |
Free Cash Flow OCF − CapEx | Not available | $-8.16M | $-22.83M | $-15.46M | $-10.08M |
Shares Outstanding | Not available | 30.11M | 320.28K | 30.11M | 30.05M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.